<HTML>
<HEAD>
<TITLE>page 35</TITLE>
<STYLE TYPE="text/css">
<!--
.pg{position:absolute;top:0px;left:0px;height:1056px;width:816px;}
BODY{font-size:13px;color:rgb(0,0,0);background-color:rgb(255,255,255);}
.ps0{position:absolute;top:1013px;left:690px;height:7px;width:21px;}
.ps1{position:absolute;top:113px;left:65px;height:11px;width:575px;}
.ps2{position:absolute;top:132px;left:65px;height:11px;width:569px;}
.ps3{position:absolute;top:150px;left:65px;height:11px;width:493px;}
.ps4{position:absolute;top:168px;left:65px;height:11px;width:545px;}
.ps5{position:absolute;top:187px;left:65px;height:11px;width:569px;}
.ps6{position:absolute;top:205px;left:65px;height:11px;width:570px;}
.ps7{position:absolute;top:223px;left:65px;height:11px;width:545px;}
.ps8{position:absolute;top:242px;left:65px;height:11px;width:540px;}
.ps9{position:absolute;top:260px;left:65px;height:11px;width:555px;}
.ps10{position:absolute;top:278px;left:65px;height:11px;width:534px;}
.ps11{position:absolute;top:297px;left:65px;height:11px;width:527px;}
.ps12{position:absolute;top:315px;left:65px;height:11px;width:560px;}
.ps13{position:absolute;top:333px;left:65px;height:11px;width:511px;}
.ps14{position:absolute;top:352px;left:65px;height:11px;width:566px;}
.ps15{position:absolute;top:370px;left:65px;height:11px;width:552px;}
.ps16{position:absolute;top:388px;left:65px;height:11px;width:559px;}
.ps17{position:absolute;top:407px;left:65px;height:11px;width:452px;}
.ps18{position:absolute;top:436px;left:65px;height:10px;width:240px;}
.ps19{position:absolute;top:453px;left:65px;height:11px;width:565px;}
.ps20{position:absolute;top:471px;left:65px;height:11px;width:569px;}
.ps21{position:absolute;top:490px;left:65px;height:11px;width:570px;}
.ps22{position:absolute;top:508px;left:65px;height:11px;width:569px;}
.ps23{position:absolute;top:526px;left:65px;height:11px;width:572px;}
.ps24{position:absolute;top:545px;left:65px;height:11px;width:577px;}
.ps25{position:absolute;top:563px;left:65px;height:11px;width:199px;}
.ps26{position:absolute;top:589px;left:65px;height:11px;width:566px;}
.ps27{position:absolute;top:608px;left:65px;height:11px;width:544px;}
.ps28{position:absolute;top:626px;left:65px;height:11px;width:564px;}
.ps29{position:absolute;top:644px;left:65px;height:11px;width:551px;}
.ps30{position:absolute;top:663px;left:65px;height:11px;width:525px;}
.ps31{position:absolute;top:681px;left:65px;height:11px;width:572px;}
.ps32{position:absolute;top:699px;left:65px;height:11px;width:536px;}
.ps33{position:absolute;top:718px;left:65px;height:11px;width:230px;}
.ps34{position:absolute;top:744px;left:65px;height:11px;width:570px;}
.ps35{position:absolute;top:762px;left:65px;height:11px;width:576px;}
.ps36{position:absolute;top:781px;left:65px;height:11px;width:575px;}
.ps37{position:absolute;top:799px;left:65px;height:11px;width:363px;}
.ps38{position:absolute;top:825px;left:65px;height:11px;width:574px;}
.ps39{position:absolute;top:844px;left:81px;height:11px;width:440px;}
.ps40{position:absolute;top:870px;left:65px;height:11px;width:518px;}
.ps41{position:absolute;top:888px;left:81px;height:11px;width:486px;}
.ps42{position:absolute;top:907px;left:81px;height:11px;width:219px;}
.ps43{position:absolute;top:115px;left:409px;height:11px;width:545px;}
.ps44{position:absolute;top:133px;left:409px;height:11px;width:559px;}
.ps45{position:absolute;top:151px;left:409px;height:11px;width:508px;}
.ps46{position:absolute;top:170px;left:409px;height:11px;width:531px;}
.ps47{position:absolute;top:188px;left:409px;height:11px;width:563px;}
.ps48{position:absolute;top:206px;left:409px;height:11px;width:503px;}
.ps49{position:absolute;top:233px;left:409px;height:11px;width:545px;}
.ps50{position:absolute;top:251px;left:409px;height:11px;width:546px;}
.ps51{position:absolute;top:269px;left:409px;height:11px;width:541px;}
.ps52{position:absolute;top:288px;left:409px;height:11px;width:273px;}
.ps53{position:absolute;top:317px;left:409px;height:10px;width:217px;}
.ps54{position:absolute;top:334px;left:409px;height:11px;width:575px;}
.ps55{position:absolute;top:352px;left:409px;height:11px;width:545px;}
.ps56{position:absolute;top:371px;left:409px;height:11px;width:499px;}
.ps57{position:absolute;top:389px;left:409px;height:11px;width:549px;}
.ps58{position:absolute;top:407px;left:409px;height:11px;width:571px;}
.ps59{position:absolute;top:426px;left:409px;height:11px;width:569px;}
.ps60{position:absolute;top:444px;left:409px;height:11px;width:568px;}
.ps61{position:absolute;top:462px;left:409px;height:11px;width:557px;}
.ps62{position:absolute;top:481px;left:409px;height:11px;width:572px;}
.ps63{position:absolute;top:499px;left:409px;height:11px;width:502px;}
.ps64{position:absolute;top:517px;left:409px;height:11px;width:495px;}
.ps65{position:absolute;top:536px;left:409px;height:11px;width:570px;}
.ps66{position:absolute;top:554px;left:409px;height:11px;width:541px;}
.ps67{position:absolute;top:572px;left:409px;height:11px;width:560px;}
.ps68{position:absolute;top:591px;left:409px;height:11px;width:533px;}
.ps69{position:absolute;top:609px;left:409px;height:11px;width:558px;}
.ps70{position:absolute;top:627px;left:409px;height:11px;width:556px;}
.ps71{position:absolute;top:646px;left:409px;height:11px;width:550px;}
.ps72{position:absolute;top:664px;left:409px;height:11px;width:323px;}
.ps73{position:absolute;top:693px;left:409px;height:10px;width:237px;}
.ps74{position:absolute;top:710px;left:409px;height:11px;width:553px;}
.ps75{position:absolute;top:729px;left:409px;height:11px;width:574px;}
.ps76{position:absolute;top:747px;left:409px;height:11px;width:546px;}
.ps77{position:absolute;top:765px;left:409px;height:11px;width:570px;}
.ps78{position:absolute;top:784px;left:409px;height:11px;width:572px;}
.ps79{position:absolute;top:802px;left:409px;height:11px;width:571px;}
.ps80{position:absolute;top:820px;left:409px;height:11px;width:552px;}
.ps81{position:absolute;top:839px;left:409px;height:11px;width:524px;}
.ps82{position:absolute;top:857px;left:409px;height:11px;width:531px;}
.ps83{position:absolute;top:875px;left:409px;height:11px;width:570px;}
.ps84{position:absolute;top:894px;left:409px;height:11px;width:546px;}
.ps85{position:absolute;top:912px;left:409px;height:11px;width:541px;}
.ps86{position:absolute;top:930px;left:409px;height:11px;width:300px;}
.ft0{font-size:8px;font-family:sans-serif;white-space:pre;}
.ft1{font-family:sans-serif;white-space:pre;}
.ft2{font-weight:bold;font-size:11px;font-family:sans-serif;white-space:pre;}
.ft3{font-size:12px;font-family:sans-serif;white-space:pre;}
.em0{font-weight:bold;font-family:"Times New Roman",Times,serif;}
.em1{}
-->
</STYLE>
<script language="JavaScript">
<!--
function MM_reloadPage(init) {  //reloads the window if Nav4 resized
  if (init==true) with (navigator) {if ((appName=="Netscape")&&(parseInt(appVersion)==4)) {
    document.MM_pgW=innerWidth; document.MM_pgH=innerHeight; onresize=MM_reloadPage; }}
  else if (innerWidth!=document.MM_pgW || innerHeight!=document.MM_pgH) location.reload();
}
MM_reloadPage(true);
// -->
</script>
</HEAD>

<BODY>
<SPAN CLASS="pg" style="width: 675px; height: 982px">
<div id="Layer1" style="position:absolute; width:167px; height:21px; z-index:1; left: 25px; top: 21px"><a href="page34wlink.htm">To 
  previous page</a></div>
</SPAN> <SPAN CLASS="ps0" style="width: 21px; top: 941; left: 650px"><SPAN CLASS="ft0">35</SPAN></SPAN> 
<SPAN CLASS="ps1" style="top: 50; left: 25px; width: 300"><SPAN CLASS="ft1">adverse 
effects of too great or too abrupt a reduc-</SPAN></SPAN> <SPAN CLASS="ps2" style="width: 300; left: 25px; top: 69"><SPAN CLASS="ft1">tion 
in blood pressure. &#160;If blood pressure remains</SPAN></SPAN> <SPAN CLASS="ps3" style="width: 300; left: 25px; top: 88"><SPAN CLASS="ft1">uncontrolled 
after 1 to 2 months, the next</SPAN></SPAN> <SPAN CLASS="ps4" style="width: 300; left: 25px; top: 107"><SPAN CLASS="ft1">dosage 
level should be prescribed. &#160;It may take</SPAN></SPAN> <SPAN CLASS="ps5" style="width: 300; left: 25px; top: 126"><SPAN CLASS="ft1">months 
to control hypertension adequately while</SPAN></SPAN> <SPAN CLASS="ps6" style="width: 300; left: 25px; top: 145"><SPAN CLASS="ft1">avoiding 
adverse effects of therapy. &#160;Most antihy-</SPAN></SPAN> <SPAN CLASS="ps7" style="width: 300; left: 25px; top: 164"><SPAN CLASS="ft1">pertensive 
medications can be given once daily,</SPAN></SPAN> <SPAN CLASS="ps8" style="width: 300; left: 25px; top: 183"><SPAN CLASS="ft1">and 
this should be the goal to improve patient</SPAN></SPAN> <SPAN CLASS="ps9" style="width: 300; left: 25px; top: 202"><SPAN CLASS="ft1">adherence. 
&#160;Home or office blood pressure mea-</SPAN></SPAN> <SPAN CLASS="ps10" style="width: 300; left: 25px; top: 221"><SPAN CLASS="ft1">surement 
in the early morning before patients</SPAN></SPAN> <SPAN CLASS="ps11" style="width: 300; left: 25px; top: 240"><SPAN CLASS="ft1">have 
taken their daily dose is useful to ensure</SPAN></SPAN> <SPAN CLASS="ps12" style="width: 300; left: 25px; top: 259"><SPAN CLASS="ft1">adequate 
modulation of the surge in blood pres-</SPAN></SPAN> <SPAN CLASS="ps13" style="width: 300; left: 25px; top: 278"><SPAN CLASS="ft1">sure 
after arising. &#160;Measurements in the late</SPAN></SPAN> <SPAN CLASS="ps14" style="width: 300; left: 25px; top: 297"><SPAN CLASS="ft1">afternoon 
or evening help monitor control across</SPAN></SPAN> <SPAN CLASS="ps15" style="width: 300; top: 316; left: 25px"><SPAN CLASS="ft1">the 
day. &#160;Treatment goals based on out-of-office</SPAN></SPAN> <SPAN CLASS="ps16" style="width: 300; left: 25px; top: 335"><SPAN CLASS="ft1">measurements 
should be lower than those based</SPAN></SPAN> <SPAN CLASS="ps17" style="width: 300; left: 25px; top: 354"><SPAN CLASS="ft1">on 
office recordings<SPAN CLASS="em1"><SUP>45<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN>&#160;(see 
chapter 2).</SPAN></SPAN> <SPAN CLASS="ps18" style="width: 240px; left: 25px; top: 383"><SPAN CLASS="ft2">Initial 
Drug Therapy</SPAN></SPAN> <SPAN CLASS="ps19" style="width: 300; left: 25px; top: 402"><SPAN CLASS="ft1"><font color="#FF0000">When 
the decision has been made to begin anti-</font></SPAN></SPAN> <SPAN CLASS="ps20" style="width: 300; left: 25px; top: 421"><SPAN CLASS="ft1"><font color="#FF0000">hypertensive 
therapy (table 5) and if there are no</font></SPAN></SPAN> <SPAN CLASS="ps21" style="width: 300; left: 25px; top: 440"><SPAN CLASS="ft1"><font color="#FF0000">indications 
for another type of drug, a diuretic or</font></SPAN></SPAN> <SPAN CLASS="ps22" style="width: 300; left: 25px; top: 459"><SPAN CLASS="ft1"><font color="#FF0000">beta-blocker 
should be chosen because numerous</font></SPAN></SPAN> <SPAN CLASS="ps23" style="width: 300; left: 25px; top: 478"><SPAN CLASS="ft1"><font color="#FF0000">randomized 
controlled trials have shown a reduc-</font></SPAN></SPAN> <SPAN CLASS="ps24" style="width: 300; left: 25px; top: 497px"><SPAN CLASS="ft1"><font color="#FF0000">tion 
in morbidity and mortality with these agents</font></SPAN></SPAN> <SPAN CLASS="ps25" style="width: 199px; left: 25px; top: 516"><SPAN CLASS="ft1"><font color="#FF0000">(figures 
6 and 7).</font></SPAN></SPAN> <SPAN CLASS="ps26" style="width: 300; left: 25px; top: 549px"><SPAN CLASS="ft1">As 
shown in table 9 and figure 8, there are com-</SPAN></SPAN> <SPAN CLASS="ps27" style="width: 300; left: 25px; top: 568px"><SPAN CLASS="ft1">pelling 
indications for specific agents in certain</SPAN></SPAN> <SPAN CLASS="ps28" style="width: 300; left: 25px; top: 588px"><SPAN CLASS="ft1">clinical 
conditions, based on outcomes data from</SPAN></SPAN> <SPAN CLASS="ps29" style="width: 300; left: 25px; top: 610px"><SPAN CLASS="ft1">RCTs. 
&#160;In other situations where outcomes data</SPAN></SPAN> <SPAN CLASS="ps30" style="width: 300; left: 25px; top: 630px"><SPAN CLASS="ft1">are 
not yet available, there are indications for</SPAN></SPAN> <SPAN CLASS="ps31" style="width: 300; left: 25px; top: 650px"><SPAN CLASS="ft1">other 
agents and the choice should be individual-</SPAN></SPAN> <SPAN CLASS="ps32" style="width: 300; left: 25px; top: 670px"><SPAN CLASS="ft1">ized, 
using the agent that most closely fits the</SPAN></SPAN> <SPAN CLASS="ps33" style="width: 230px; left: 25px; top: 692"><SPAN CLASS="ft3">patient&#146;s 
needs.<SPAN CLASS="em1"><SUP>134<SPAN CLASS="em0">Pr</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps34" style="width: 300; left: 25px; top: 722"><SPAN CLASS="ft1">If 
the response to the initial drug choice is inade-</SPAN></SPAN> <SPAN CLASS="ps35" style="width: 300; left: 25px; top: 742"><SPAN CLASS="ft1">quate 
after reaching the full dose, two options for</SPAN></SPAN> <SPAN CLASS="ps36" style="width: 300; left: 25px; top: 762"><SPAN CLASS="ft1">subsequent 
therapy should be considered (see fig-</SPAN></SPAN> <SPAN CLASS="ps37" style="width: 300; left: 25px; top: 782px"><SPAN CLASS="ft1">ure 
8 for treatment algorithm):</SPAN></SPAN> <SPAN CLASS="ps38" style="width: 300; left: 25px; top: 810px"><SPAN CLASS="ft1">&#149;&#160;&#160;If 
the patient is tolerating the first choice well,</SPAN></SPAN> <SPAN CLASS="ps39" style="width: 284px; left: 41px; top: 831px; height: 11px"><SPAN CLASS="ft1">add 
a second drug from another class.</SPAN></SPAN> <SPAN CLASS="ps40" style="top: 851px; left: 25px; width: 300"><SPAN CLASS="ft1">&#149;&#160;&#160;If 
the patient is having significant adverse</SPAN></SPAN> <SPAN CLASS="ps41" style="width: 284px; left: 41px; height: 11px; top: 871px"><SPAN CLASS="ft1">effects 
or no response, substitute an agent</SPAN></SPAN> <SPAN CLASS="ps42" style="left: 41px; top: 891px"><SPAN CLASS="ft1">from 
another class.</SPAN></SPAN> <SPAN CLASS="ps43" style="top: 50px; width: 300px; left: 369px"><SPAN CLASS="ft1">If 
a diuretic is not chosen as the first drug, it is</SPAN></SPAN> <SPAN CLASS="ps44" style="width: 300; left: 369px; top: 69px"><SPAN CLASS="ft1">usually 
indicated as a second-step agent because</SPAN></SPAN> <SPAN CLASS="ps45" style="width: 300; top: 88px; left: 369px"><SPAN CLASS="ft1">its 
addition will enhance the effects of other</SPAN></SPAN> <SPAN CLASS="ps46" style="width: 300; top: 107px; left: 369px"><SPAN CLASS="ft1">agents. 
&#160;If addition of a second agent controls</SPAN></SPAN> <SPAN CLASS="ps47" style="width: 300; top: 126px; left: 369px"><SPAN CLASS="ft1">blood 
pressure satisfactorily, an attempt to with-</SPAN></SPAN> <SPAN CLASS="ps48" style="width: 300; top: 145px; left: 369px"><SPAN CLASS="ft1">draw 
the first agent may be considered.<SPAN CLASS="em1"><SUP>135<SPAN CLASS="em0">F</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps49" style="width: 300; top: 172px; left: 369px"><SPAN CLASS="ft1">Before 
proceeding to each successive treatment</SPAN></SPAN> <SPAN CLASS="ps50" style="width: 300; top: 191px; left: 369px"><SPAN CLASS="ft1">step, 
clinicians should consider possible reasons</SPAN></SPAN> <SPAN CLASS="ps51" style="width: 300; top: 210px; left: 369px"><SPAN CLASS="ft1">for 
lack of responsiveness to therapy, including</SPAN></SPAN> <SPAN CLASS="ps52" style="width: 273px; top: 229px; left: 369px"><SPAN CLASS="ft1">those 
listed in table 12.</SPAN></SPAN> <SPAN CLASS="ps53" style="width: 217px; top: 256px; left: 369px"><SPAN CLASS="ft2">High-Risk 
Patients</SPAN></SPAN> <SPAN CLASS="ps54" style="top: 275px; width: 300px; left: 369px"><SPAN CLASS="ft1">Although 
similar general approaches are advocat-</SPAN></SPAN> <SPAN CLASS="ps55" style="top: 294px; width: 300px; left: 369px"><SPAN CLASS="ft1">ed 
for all patients with hypertension, modifica-</SPAN></SPAN> <SPAN CLASS="ps56" style="top: 313px; width: 300px; left: 369px"><SPAN CLASS="ft1">tions 
may be needed for those with stage 3</SPAN></SPAN> <SPAN CLASS="ps57" style="top: 332px; width: 300px; left: 369px"><SPAN CLASS="ft1">hypertension, 
those in risk group C, or those at</SPAN></SPAN> <SPAN CLASS="ps58" style="top: 351px; width: 300px; left: 369px"><SPAN CLASS="ft1">especially 
high risk for a coronary event or stroke</SPAN></SPAN> <SPAN CLASS="ps59" style="top: 370px; width: 300px; left: 369px"><SPAN CLASS="ft1">(table 
5). &#160;Drug therapy should begin with mini-</SPAN></SPAN> <SPAN CLASS="ps60" style="top: 389px; width: 300px; left: 369px"><SPAN CLASS="ft1">mal 
delay. &#160;Although some patients may respond</SPAN></SPAN> <SPAN CLASS="ps61" style="top: 408px; width: 300px; left: 369px"><SPAN CLASS="ft1">adequately 
to a single drug, it is often necessary</SPAN></SPAN> <SPAN CLASS="ps62" style="top: 427px; width: 300px; left: 369px"><SPAN CLASS="ft1">to 
add a second or third agent after a short inter-</SPAN></SPAN> <SPAN CLASS="ps63" style="top: 446px; width: 300px; left: 369px"><SPAN CLASS="ft1">val 
if control is not achieved. &#160;The intervals</SPAN></SPAN> <SPAN CLASS="ps64" style="top: 465px; width: 300px; left: 369px"><SPAN CLASS="ft1">between 
changes in the regimen should be</SPAN></SPAN> <SPAN CLASS="ps65" style="top: 484px; width: 300px; left: 369px"><SPAN CLASS="ft1">decreased, 
and the maximum dose of some drugs</SPAN></SPAN> <SPAN CLASS="ps66" style="top: 503px; width: 300px; left: 369px"><SPAN CLASS="ft1">may 
be increased. &#160;In some patients, it may be</SPAN></SPAN> <SPAN CLASS="ps67" style="top: 522px; width: 300px; left: 369px"><SPAN CLASS="ft1">necessary 
to start treatment with more than one</SPAN></SPAN> <SPAN CLASS="ps68" style="top: 541px; width: 300px; left: 369px"><SPAN CLASS="ft1">agent. 
&#160;Patients with average SBP of 200 mm</SPAN></SPAN> <SPAN CLASS="ps69" style="top: 560px; width: 300px; left: 369px"><SPAN CLASS="ft1">Hg 
or greater and average DBP of 120 mm Hg</SPAN></SPAN> <SPAN CLASS="ps70" style="top: 579px; width: 300px; left: 369px"><SPAN CLASS="ft1">or 
greater require more immediate therapy and,</SPAN></SPAN> <SPAN CLASS="ps71" style="top: 598px; width: 300px; left: 369px"><SPAN CLASS="ft1">if 
symptomatic target organ damage is present,</SPAN></SPAN> <SPAN CLASS="ps72" style="top: 617px; width: 300px; left: 369px"><SPAN CLASS="ft1">may 
require hospitalization.</SPAN></SPAN> <SPAN CLASS="ps73" style="top: 644px; left: 369px"><SPAN CLASS="ft2">Step-Down 
Therapy</SPAN></SPAN> <SPAN CLASS="ps74" style="top: 663px; width: 300px; left: 369px"><SPAN CLASS="ft1">An 
effort to decrease the dosage and number of</SPAN></SPAN> <SPAN CLASS="ps75" style="top: 682px; width: 300px; left: 369px"><SPAN CLASS="ft1">antihypertensive 
drugs should be considered after</SPAN></SPAN> <SPAN CLASS="ps76" style="top: 701px; width: 300px; left: 369px"><SPAN CLASS="ft1">hypertension 
has been controlled effectively for</SPAN></SPAN> <SPAN CLASS="ps77" style="top: 720px; width: 300px; left: 369px"><SPAN CLASS="ft1">at 
least 1 year. &#160;The reduction should be made in</SPAN></SPAN> <SPAN CLASS="ps78" style="top: 739px; width: 300px; left: 369px"><SPAN CLASS="ft1">a 
deliberate, slow, and progressive manner. &#160;Step-</SPAN></SPAN> <SPAN CLASS="ps79" style="top: 758px; width: 300px; left: 369px"><SPAN CLASS="ft1">down 
therapy is more often successful in patients</SPAN></SPAN> <SPAN CLASS="ps80" style="top: 777px; width: 300px; left: 369px"><SPAN CLASS="ft1">who 
also are making lifestyle modifications.<SPAN CLASS="em1"><SUP>80<SPAN CLASS="em0">Ra</SPAN></SUP></SPAN></SPAN></SPAN> 
<SPAN CLASS="ps81" style="top: 796px; width: 300px; left: 369px"><SPAN CLASS="ft1">Patients 
whose drugs have been discontinued</SPAN></SPAN> <SPAN CLASS="ps82" style="top: 815px; width: 300px; left: 369px"><SPAN CLASS="ft1">should 
have scheduled followup visits because</SPAN></SPAN> <SPAN CLASS="ps83" style="top: 834px; width: 300px; left: 369px"><SPAN CLASS="ft1">blood 
pressure usually rises again to hypertensive</SPAN></SPAN> <SPAN CLASS="ps84" style="top: 853px; width: 300px; left: 369px"><SPAN CLASS="ft1">levels, 
sometimes months or years after discon-</SPAN></SPAN> <SPAN CLASS="ps85" style="top: 872; width: 300px; left: 369px"><SPAN CLASS="ft1">tinuance, 
especially in the absence of sustained</SPAN></SPAN> <SPAN CLASS="ps86" style="top: 891px; left: 369px"><SPAN CLASS="ft1">improvements 
in lifestyle.</SPAN></SPAN> 
</BODY>

</HTML>
